Tue, Sep 16, 2014, 9:54 AM EDT - U.S. Markets close in 6 hrs 6 mins

Recent

% | $
Quotes you view appear here for quick access.

Celgene Corp. (CELG) Message Board

  • rob_cos rob_cos Oct 17, 2013 10:08 AM Flag

    Barclays this am "We expect Abraxane will become the standard-of-care in front-line pancreatic cancer - unlike FOLFIRINOX, it will be widely

    Barclays this am
    "We expect Abraxane will become the standard-of-care in front-line pancreatic cancer - unlike FOLFIRINOX, it will be widely used due to its consistent benefit across all types of patients"
    We expect Abraxane will become the standard-of-care in front-line pancreatic cancer:The results from the MPACT study lead us to believe that the benefits with treatment outweigh the risks. We expect Abraxane plus gemcitabine to be widely used due to its consistent benefit across all types of patients; this is in contrast to FOLFIRINOX which has been shown to be too toxic for a majority of patients. We estimate worldwide peak sales in pancreatic cancer of $1.15bn, assuming 50% market penetration in the metastatic setting and 25% in locally-advanced patients.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CELG
90.8897+1.4297(+1.60%)9:54 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.